insulin aspart

This medicine is authorised for use in the European Union.


NovoMix is a range of insulin medicines used to treat patients who have diabetes and need insulin to keep their blood glucose (sugar) level controlled. NovoMix medicines contain the active substance insulin aspart (100 units/ml) combined with protamine to make it longer acting. It is available as:

  • NovoMix 30 (30% insulin aspart and 70% insulin aspart protamine)
  • NovoMix 50 (50% insulin aspart and 50% insulin aspart protamine)
  • NovoMix 70 (70% insulin aspart and 30% insulin aspart protamine).

NovoMix 30 can be used in patients from 10 years of age. NovoMix 50 and NovoMix 70 can only be used in adults (from 18 years of age).

This EPAR was last updated on 29/08/2023

Authorisation details

Product details
Agency product number
Active substance
insulin aspart
International non-proprietary name (INN) or common name
insulin aspart
Therapeutic area (MeSH)
Diabetes Mellitus
Anatomical therapeutic chemical (ATC) code
Publication details
Marketing-authorisation holder
Novo Nordisk A/S
Date of issue of marketing authorisation valid throughout the European Union
Contact address
Novo Allé
DK-2880 Bagsværd

Product information

22/05/2023 NovoMix - EMEA/H/C/000308 - IB/0115

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Drugs used in diabetes

Therapeutic indication

Treatment of diabetes mellitus.

Assessment history

How useful was this page?

Add your rating
3 ratings
1 rating
1 rating